Multiple sclerosis in sarcoidosis patients: Two case reports

Masoud Etemadifar1 | Armin Mehri1 | Nahad Sedaghat1 | Mehri Salari2 | Parsa Tavassoli Naini1

Abstract
Two cases of sarcoidosis referred to our clinic with neurological symptoms. They were diagnosed with multiple sclerosis using non-invasive studies. The first patient refused treatment and died of myocardial infarction 6 months after visiting our clinic. The second received interferon-beta and methotrexate with a favorable outcome after 3 years. Since the possible similar presentation of the two conditions could appear indistinct for certain diagnosis, accurate evaluation of symptoms and paraclinical data can provide the best approach to each condition.

Keywords
case report, multiple sclerosis, neurosarcoidosis, sarcoidosis

1Neurosurgery Research Department, Alzahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
2Functional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Correspondence
Parsa Tavassoli Naini, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. Email: parsatavassoli2000@gmail.com

1 of 6
diagnostic and treatment approach along with previous studies could guide clinicians in the future to identify and manage such rare events properly.

2 | CASE PRESENTATION 1

A 53-year-old woman presented to our clinic in March 2019 for evaluation of lower limb weaknesses along with visual impairments starting from 2 months earlier. She was married with three children, had a history of a face lesion 5 years prior, for which she had visited a dermatologist. At that time, she was diagnosed with sarcoidosis based on a histopathological study of the lesion biopsy which revealed a pattern of non-caseating granulomatous inflammation consistent with sarcoidosis, a chest CT study which found mild pleural thickening and hilar prominence on the right side, and serum angiotensin-converting enzyme (ACE) level measurement, which was within normal range but close to the upper limit. Since then, she was put on oral prednisolone therapy. From the time she was diagnosed with sarcoidosis, she reported experiencing several episodes of ataxia, diplopia, and upper limb weakness, each lasting between 2 and 4 weeks. Those episodes were deemed due to NS and treated accordingly in other clinics. She also developed hypertension and diabetes mellitus, otherwise, her past medical, social, and familial histories were unremarkable. Neurological examination revealed glove and stocking sensory impairment and lower limb weakness with a distal force of 3/5 and proximal force of 5/5. Babinski sign was observed bilaterally and tendon reflexes were brisk. Considering NS, diabetic neuropathy, and MS as the primary differential diagnoses, nerve conduction velocity (NCV) studies, visual-evoked potential test (VEP), and MRI were performed. NCV showed demyelinating polyneuropathy in the lower extremities, VEP results were 192 and 194 in the left and right eye, respectively, and showed prolongation of latency bilaterally. MRI study showed multiple demyelinating lesions in the periventricular, juxtacortical, and cervical spine areas (Figure 1). Although some findings could have been explained by diabetic neuropathy and/or NS, the clinical course of the illness and the location and features of the lesions in MRI were consistent with, and typical of MS; therefore, in accordance with the McDonald criteria, diagnosis of relapsing–remitting MS was made. CSF analysis for detection of oligoclonal bands (OCB) was not performed, as the patient was non-consensual for a lumbar puncture, and already fulfilled the criteria of dissemination in space and time. She was offered rituximab therapy but refused to undergo the treatment. Unfortunately, the patient died at the age of 54 reportedly due to myocardial infarction—6 months after visiting our clinic.

3 | CASE PRESENTATION 2

In July 2019, a 60-year-old woman presented to our clinic with lower limb weakness, paresthesia, and urinary incontinence. She was widowed with one child, had a past medical history of right facial paralysis 14 years prior diagnosed as Bell’s palsy. Then, she started to develop intermittent inflammations in both knees, and also a sharp focal pain in the left side of the chest, which intensified with respiration. Subsequently, chest radiograph and CT scans showed left pleural thickening consistent with pleurisy, and small nodular lesions in the right lung. Pathological study of the lesion needle biopsy showed non-caseating granulomatous inflammatory reaction, serum ACE was measured to be close to the upper limit of the normal range, and tuberculosis workups were negative. Back then, she was diagnosed with sarcoidosis, and was taking oral prednisolone ever

FIGURE 1 Case 1: fluid-attenuated inversion recovery (FLAIR) MRI sequences showing high-intensity areas in paraventricular and para-spinal regions.
since. She had been experiencing neurological episodes from time to time since then, each lasting a few weeks as she stated. For which, she visited a nearby clinic, was diagnosed with NS, and was treated accordingly. Other medical, social, and family histories were unremarkable. Neurological examination showed lower limb weakness and bilateral Babinski sign. No sensory level was apparent. Considering NS, tumors, and MS as the most probable diagnoses, MRI was performed, which showed cervical spine, periventricular (Dawson fingers), and juxtacortical demyelinating lesions suggestive of MS (Figure 2). As she also fulfilled the dissemination in time criterion, based on the McDonald criteria, she was diagnosed with MS without CSF analysis to determine the presence of OCBs. She was prescribed weekly Interferon beta-1a injections which she complied with. After consulting a pulmonologist, adding methotrexate to the treatment plan was suggested and was done. In her last subsequent follow-up in June 2022, she was in good condition with complete resolution of her lower limb weaknesses, no additional relapses, an expanded disability status scale score of 1.5, stable breathing with no dyspnea at rest, and no other major problems.

4 | DISCUSSION

Sarcoidosis can produce several heterogenous clinical pictures, stemming from the multisystem nature of the disease. NS is uncommon, but also a potentially serious form of sarcoidosis. While NS mostly affects cranial nerves, it can also involve other parts of nervous system, including intracranial structures. The clinical manifestations in an individual depends on the location of the inflammatory process. The most commonly reported features of NS include cranial nerve neuropathy, headache, fatigue, nausea and vomiting, sensory abnormalities like visual disturbance, motor symptoms consisting of hemiparesis and paraparesis, meningitis, seizures, and spinal cord abnormalities.20-23 NS can mimic a wide range of other neurological diseases such as neoplasms, infections, angiitis/vasculitis and demyelinating diseases—including MS.22-23 For instance, Serrano and colleagues report a patient, in whom NS was initially misdiagnosed as probable MS.24 Their case did not fulfill the criterion of dissemination in time, and was therefore followed up on a regular basis until diagnosed with sarcoidosis in a subsequent workup for cough and dyspnea.24 Apart from the characteristics and location of the lesions, Serrano et al.’s case demonstrates the importance of the dissemination in time criterion in discriminating MS from NS—although NS could also show a relapsing–remitting clinical course. CSF OCB are also a powerful discriminator of MS from NS as suggested by Arun et al.,25 but they also may turn out positive in NS cases.25

Furthermore, although cases of sarcoidosis in people with preexisting MS—particularly deemed, but not proven to be associated with certain DMTs—and NS cases mimicking MS have been frequently reported in the literature, few cases of MS have been reported in patients with preexisting sarcoidosis (Table 1). In known sarcoidosis patients who develop a chronic neurologic illness, “there is a tendency to assume that NS is the highest possibility” as stated by Tyshkov and colleagues.14 Remarkably, diagnosing MS in known sarcoidosis patients may be of a greater challenge than diagnosing sarcoidosis in known MS patients—as unlike the former, subsequent development of sarcoidosis in the later cases could be detected and confirmed based on extra-nervous findings. Furthermore, misdiagnosing MS as NS delays and further complicates a correct diagnosis of MS, as MS becomes less prevalent in higher ages—especially in ages above 50—and neurological illness at higher ages are less
likely to be deemed because of MS; for example, our cases were diagnosed above the age of 50, but could not be classified as late-onset MS as their symptoms developed before the age of 50. This might as well be the reason that the later has been more frequently reported in the literature. In presence of such challenges, a thorough neurological evaluation and determination of the true date of symptom onset, along with imaging, electrophysiological studies, and CSF analysis seem to be reasonable before marking sarcoidosis patients who develop a neurological illness as NS cases. Nevertheless, in cases of coexistence or uncertain diagnosis, a practical approach could be treatment options that benefit both conditions, for example, methotrexate therapy as done in our second case with a favorable outcome after 3 years.

Finally, no underlying mechanistic correlation between sarcoidosis and MS has been confirmed to date, although both are thought to involve genetic and immune-mediated etiologies. Although not established, the HLA loci may be involved in both MS and sarcoidosis. Further studies may provide clues to any common genetic links between the two diseases and provide useful guidance regarding disease pathology and effective therapy.

TABLE 1 Summary of studies reporting MS in patients with preexisting sarcoidosis

| Reference (location) | Age upon diagnosis (years) | Initial presentation of sarcoidosis | Initial neurologic symptoms | MRI findings | Other findings | Method of final differentiation of MS from NS |
|----------------------|---------------------------|----------------------------------|-----------------------------|--------------|---------------|------------------------------------------|
| 37 (Croatia)         | MS: 49                    | LAD                              | Lower limb weakness and numbness | Demyelinating lesions in brain | Non-specific laboratory findings, no information on presence of OCB in CSF | Treatment trials, clinical course |
| 14 (USA)             | MS: 30                    | Löfgren syndrome                 | Hemifacial numbness         | Demyelinating lesions in brain and spinal cord | Not specified | MS-typical lesions, clinical course, CSF analysis |
| Present report (Iran) | MS: 53                    | Skin lesion                      | Gait ataxia, diplopia and upper limb weakness | Demyelinating lesions in brain and spinal cord | Slowed NCV in lower extremities, Latency prolongation of VEP in both eyes, no information on presence of OCB in CSF | Treatment trials, MS-typical lesions, clinical course |
| Present report (Iran) | MS: 60                    | Pleurisy, knee inflammation      | Lower limb weakness and gait ataxia | Demyelinating lesions in brain and spinal cord | Non-specific laboratory findings, no information on presence of OCB in CSF | Treatment trials, MS-typical lesions, clinical course |

Abbreviations: CSF, cerebrospinal fluid; LAD, lymphadenopathy; MRI, magnetic resonance imaging; MS, multiple sclerosis; NCV, nerve conduction velocity; NS, neurosarcoidosis; OCB, oligoclonal bands; VEP, visual-evoked potentials.
CONSENT
The patients or their next of kin provided written consent for publication of their anonymized cases.

ORCID
Nahad Sedaghat https://orcid.org/0000-0002-2796-6791
Mehri Salari https://orcid.org/0000-0002-1675-681X
Parsa Tavassoli Naini https://orcid.org/0000-0002-2881-8870

REFERENCES
1. Henke CE, Henke G, Elveback LR, Beard M, Ballard DJ, Kurland LT. The epidemiology of sarcoidosis in Rochester, Minnesota: a population-based study of incidence and survival. Am J Epidemiol. 1986;123(5):840-845.
2. Baughman R, Lower E, du Bois RM. Sarcoidosis. Lancet. 2003;361(9363):1111-1118.
3. Newman LS, Rose CS, Bresnitz EA, et al. A case control etiology and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology. 1996;47(6):1531-1534.

4. Tsykhov C, Pawate S, Bradshaw MJ, et al. Multiple sclerosis and sarcoidosis: a case for coexistence. Neurol Clin Pract. 2019;9(3):218-227.
5. Iannuzzi MC, Rybicki BA, Teirstein AS. Medical progress. Am J Respir Crit Care Med. 1999;53(3):457.
6. Mitchell J, Yap P, Milne L, Lachmann P, Pentland B. Immunological studies on the cerebrospinal fluid in neurological sarcoidosis. J Neuroimmunol. 1984;7:249-253.
7. Group LMSS, Group TUBMCMA. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology. 1999;53(3):457.
8. Group LMSS, Group TUBMCMA. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology. 1999;53(3):457.
9. Scott TF. Neurosarcoidosis mimery of MS: Clues from cases with CNS tissue diagnosis. J Neuro Sci. 2021;429:117621. doi:10.1016/j.jns.2021.117621
10. Reske D, Peterie HF, Heiss WD. Difficulties in the differentiation of chronic inflammatory diseases of the central nervous system—value of cerebrospinal fluid analysis and immunological abnormalities in the diagnosis. Acta Neurol Scand. 2005;112(4):207-213.
11. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-173.
12. Group LMSS, Group TUBMCMA. TNF neutralization in MS: a case report. Malaysian J Med Health Sci. 2020;16(10):81-83.
13. Sukur NA, Sahari NS, Marwan AA, Ismail R. A rare case of disseminated sarcoidosis presenting with neurosarcoidosis: a case report. Mult Scler Relat Disord. 2018;7:91-94. doi:10.1016/j.msard.2018.07.007
14. Zajicek J, Scolding N, Foster O, et al. Central nervous system sarcoidosis—diagnosis and management. QJM. 1999;92(2):103-117.
15. Zajicek J, Scolding N, Foster O, et al. Central nervous system sarcoidosis—diagnosis and management. QJM. 1999;92(2):103-117.
16. Zajicek J, Scolding N, Foster O, et al. Central nervous system sarcoidosis—diagnosis and management. QJM. 1999;92(2):103-117.
32. Scott TF, Yandora K, Kunschner LJ, Schramke C. Neurosarcoidosis mimicry of multiple sclerosis: clinical, laboratory, and imaging characteristics. Neurologist. 2010;16(6):386-389. doi:10.1097/NRL.0b013e3181b287df
33. Carmody RF, Mafee MF, Goodwin JA, Small K, Haery C. Orbital and optic pathway sarcoidosis: MR findings. AJNR Am J Neuroradiol. 1994;15(4):775-783.
34. Metyas S, Tawadrous M, Yeter KC, Arkfeld DG. Neurosarcoidosis mimicking multiple sclerosis successfully treated with methotrexate and adalimumab. Int J Rheum Dis. 2014;17(2):214-216. doi:10.1111/1756-185x.12122
35. Chan F, Riminton DS, Ramanathan S, Reddel SW, Hardy TA. Distinguishing CNS neurosarcoidosis from multiple sclerosis and an approach to "overlap" cases. J Neuroimmunol. 2022;369:577904. doi:10.1016/j.jneuroim.2022.577904
36. Inojosa H, Schriefer D, Ziemssen T. Clinical outcome measures in multiple sclerosis: a review. Autoimmun Rev. 2020;19(5):102512.
37. Prenc LR, Telarović S, Vidović I, Sepčić J, Peteh LL. Coexistence of neurosarcoidosis and multiple sclerosis. Neurol Croat. 2012;61:3-4.

How to cite this article: Etemadifar M, Mehri A, Sedaghat N, Salari M, Tavassoli Naini P. Multiple sclerosis in sarcoidosis patients: Two case reports. Clin Case Rep. 2022;10:e06332. doi: 10.1002/ccr3.6332